
INBX Stock Forecast & Price Target
INBX Analyst Ratings
Bulls say
Inhibrx Biosciences is viewed positively because its proprietary multivalent protein-engineering platform is producing clinically differentiated data where earlier DR5 and OX40 approaches often failed, supporting the idea that its candidates better balance potency and safety. Ozekibart showed a 52% reduction in the risk of progression or death, more than doubled median PFS to 5.52 months versus 2.66 months, and has an FDA-accepted BLA with a PDUFA date of April 14, 2027, while INBRX-106 lifted cORR to 44.0% versus 21.4% for Keytruda alone. Despite a 3Q26 net loss of $2.46 per share and cash of about $199.5 million, the balance sheet appears strong enough to fund multiple catalysts, with R&D and SG&A of $26.0 million and $7.8 million, respectively.
Bears say
Inhibrx Biosciences is viewed negatively because it has never been profitable and continues to post sizable losses, with net loss per share figures including (2.80), (1.85), and (9.04), underscoring a business model that has not yet proven self-sustaining. The company may need to raise additional capital to fund operations, and if it cannot secure financing, it faces going-concern risk, which materially weakens the investment case. It also competes in the increasingly crowded bispecific construct arena against better-resourced rivals, and even encouraging initial data may not be enough if future clinical results fail to differentiate the pipeline.
This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
INBX Analyst Forecast & Price Prediction
Start investing in INBX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Inhibrx Biosciences Inc (INBX) Forecast
INBX Analyst Forecast & Price Prediction
Start investing in INBX
Order type
Buy in
Order amount
Est. shares
0 shares